Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, Deeks SG.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):389-93. doi: 10.1097/QAI.0b013e3181c42ea4.

PMID:
20300008
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Characterization and structural analysis of HIV-1 integrase conservation.

Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.

AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.

PMID:
19290031
[PubMed - indexed for MEDLINE]
3.

[Resistance to integrase inhibitors].

Garrido C, de Mendoza C, Soriano V.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:40-6. Review. Spanish.

PMID:
19572425
[PubMed - indexed for MEDLINE]
4.

HIV resistance to raltegravir.

Clavel F.

Eur J Med Res. 2009 Nov 24;14 Suppl 3:47-54. Review.

PMID:
19959417
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
[PubMed - indexed for MEDLINE]
6.

[Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].

Delaugerre C.

Med Mal Infect. 2010 Sep;40 Suppl 1:S1-10. doi: 10.1016/S0399-077X(10)70001-9. Review. French.

PMID:
20800182
[PubMed - indexed for MEDLINE]
7.

Emerging patterns and implications of HIV-1 integrase inhibitor resistance.

Geretti AM, Armenia D, Ceccherini-Silberstein F.

Curr Opin Infect Dis. 2012 Dec;25(6):677-86. doi: 10.1097/QCO.0b013e32835a1de7. Review.

PMID:
23086187
[PubMed - indexed for MEDLINE]
8.

Raltegravir: the first HIV integrase inhibitor.

Cocohoba J, Dong BJ.

Clin Ther. 2008 Oct;30(10):1747-65. doi: 10.1016/j.clinthera.2008.10.012. Review.

PMID:
19014832
[PubMed - indexed for MEDLINE]
9.

HIV-1 integrase inhibitors: a review of their chemical development.

Ingale KB, Bhatia MS.

Antivir Chem Chemother. 2011 Nov 17;22(3):95-105. doi: 10.3851/IMP1740. Review.

PMID:
22095518
[PubMed - indexed for MEDLINE]
10.

[How proviral DNA is integrated into the host cell DNA and how this process can be inhibited].

Mirambeau G.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:11-6. Review. Spanish.

PMID:
19572420
[PubMed - indexed for MEDLINE]
11.

Raltegravir: in treatment-naive patients with HIV-1 infection.

Croxtall JD, Scott LJ.

Drugs. 2010 Mar 26;70(5):631-42. doi: 10.2165/11204590-000000000-00000. Review.

PMID:
20329808
[PubMed - indexed for MEDLINE]
12.

Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.

Fischl MA.

AIDS. 1999 Sep;13 Suppl 1:S49-59. Review.

PMID:
10546785
[PubMed - indexed for MEDLINE]
13.

Resistance to novel drug classes.

Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V.

Curr Opin HIV AIDS. 2009 Nov;4(6):531-7. doi: 10.1097/COH.0b013e328331d4b1. Review.

PMID:
20048722
[PubMed - indexed for MEDLINE]
14.

HIV type 1 integrase inhibitors: from basic research to clinical implications.

Jegede O, Babu J, Di Santo R, McColl DJ, Weber J, QuiƱones-Mateu M.

AIDS Rev. 2008 Jul-Sep;10(3):172-89. Review.

PMID:
18820719
[PubMed - indexed for MEDLINE]
15.

Dolutegravir for the treatment of HIV.

Katlama C, Murphy R.

Expert Opin Investig Drugs. 2012 Apr;21(4):523-30. doi: 10.1517/13543784.2012.661713. Epub 2012 Mar 2. Review.

PMID:
22380682
[PubMed - indexed for MEDLINE]
16.

Allosteric inhibitor development targeting HIV-1 integrase.

Al-Mawsawi LQ, Neamati N.

ChemMedChem. 2011 Feb 7;6(2):228-41. doi: 10.1002/cmdc.201000443. Epub 2011 Jan 12. Review.

PMID:
21275045
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk